Nghe An officials meeting with the SK Group delegation to discuss the proposed investment. Photo: Nghe An province The Nghe An government held a working session with a delegation from SK Group, led by ...

Why did two private equity firms with more than $460 billion under management want a little old gene therapy biotech called ...

SOMERVILLE, Mass., May 16, 2025--As previously announced on May 14, 2025, Carlyle (NASDAQ: CG) ("Carlyle"), SK Capital Partners, LP ("SK Capital") and bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird ...

Carlyle Media: Brittany Berliner (212) 813-4839 [email protected] SK Capital Ben Dillon (646)-278-1353 [email protected] Source: bluebird bio, Inc.

SK Capital’s portfolio of businesses generates revenues of approximately $12 billion annually, employs more than 25,000 people globally, and operates more than 200 plants in over 30 countries.

Thrive Capital is raising money for a company it has created called Thrive Holdings, which is meant to develop and buy start-ups, according to four people with knowledge of the matter.

SK Capital’s portfolio of businesses generates revenues of approximately $12 billion annually, employs more than 25,000 people globally, and operates more than 200 plants in over 30 countries.

Carlyle and SK Capital Partners have agreed to pay $3 in cash for each share of Bluebird, the biotech announced Friday. That price is a 57% discount to the company’s closing stock price Thursday.